Person:
SEÇKİN GENÇOSMANOĞLU, DİLEK

Organizational Units

Organizational Unit

Tıp Fakültesi

Last Name

SEÇKİN GENÇOSMANOĞLU

First Name

DİLEK

Full item page

Search Results

Now showing 1 - 10 of 11

Open Access
Erlotinib induced ectropion following papulopustular rash
(SPECJALISCI DERMATOLODZY, 2015-06-30) SALMAN, ANDAÇ; Salman, Andac; Cerman, Eren; Seckin, Dilek; Kanitez, Metin
Background: Erlotinib is a targeted anti-cancer drug which acts through the inhibition of epidermal growth factor receptor (EGFR). Main observations: A 79-year-old developed bilateral ectropion after he received erlotinib treatment for lung adenocarcinoma. The ectropion completely resolved with symptomatic treatment without any modification in erlotinib therapy. Conclusions: EGFR inhibitors are frequently associated with a variety of mucocutaneous adverse events. Ocular toxicity associated with these agents has been reported rarely. We present this case to underline the importance of recognition of newly reported cutaneous and ocular adverse events of targeted therapies.
Open Access
Drug eruption: A mimicker of Coronavirus disease-2019 rash
(2022-01-01) ERGUN, SAFİYE ATLAS TÜLİN; SEVEN, SEDA; SEÇKİN GENÇOSMANOĞLU, DİLEK; TİGEN, ELİF; AKTAŞ, MERYEM; ERGUN S. A. T., Ergenc I., SEVEN S., SEÇKİN GENÇOSMANOĞLU D., CÖMERT ÖZER E., AKTAŞ M., TİGEN E.
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight dues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research.
Open Access
Growth Arrest-Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis
(WILEY, 2015-04) SEÇKİN GENÇOSMANOĞLU, DİLEK; Sunbul, Murat; Cagman, Zeynep; Gerin, Fethullah; Ozgen, Zuleyha; Durmus, Erdal; Seckin, Dilek; Ahmad, Sarfraz; Uras, Fikriye; Agirbasli, Mehmet
ObjectivesAn increased risk for cardiovascular disease with psoriasis has been reported. Growth Arrest-Specific 6 (GAS6) amplifies pro-inflammatory endothelial cell activation via TAM receptors. However, it also inhibits inflammation by multiple mechanisms including phagocytosis. The objective of this study was to investigate whether plasma GAS6 levels are associated with conventional cardiometabolic (CM) risk factors in patients with psoriasis. MethodsForty patients diagnosed with psoriasis (22 male, mean age: 43.313.8years) and 40 age-/sex-matched healthy controls (22 male, mean age: 39.38.9years) were included in the study. CM risk factors (hypertension, hyperlipidemia, diabetes mellitus, and cigarette smoking) were identified. GAS6 levels were measured by ELISA. ResultsThere were no significant differences between the plasma GAS6 levels of patients with psoriasis compared to the control group (6.6 +/- 2.0ng/mL, 7.6 +/- 2.8ng/mL, respectively, P>0.05). However, GAS6 levels of patients with psoriasis having a smoking history (n=11) were significantly lower than both patients with psoriasis who had no smoking history (n=29) and controls (5.5 +/- 1.7ng/mL, 6.9 +/- 1.9ng/mL, 7.6 +/- 2.8ng/mL, respectively, P<0.05). Similarly, psoriasis patients with at least one CM risk factor showed lower GAS6 levels compared to subjects without any CM risk factor (5.7 +/- 1.7ng/mL, 7.3 +/- 2.0ng/mL, P<0.01). There was no correlation between the GAS6 level, disease duration or PASI score (r=0.150, -0.150, and P=0.310, 0.398, respectively). ConclusionsThis pilot study provides the first evidence in humans for an association between low plasma GAS6 levels and conventional risk factors in psoriasis. Further large scale, prospective studies are needed to confirm these results.
Open Access
Current Approach to Phototherapy Applications in Dermatology Practice: Part 1. History, Lamps, Ultraviolet Radiation Levels Measurement and Phototherapy Modalities
(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2017-03-15) SEÇKİN GENÇOSMANOĞLU, DİLEK; Gencosmanoglu, Dilek Seckin
Lately, important advances take place in dermatological treatment. Phototherapy, as one of the oldest treatment modalities in the history of dermatology, does not fall behind these advances; on the contrary, it is still used widely in the treatment of many skin diseases with the advantages of being effective and safe. This article aims to give practical and basic information about artificial ultraviolet sources, dosimetry and calibration standards of these sources and ultraviolet treatment protocols, starting with the history of current phototherapy modalities.
Open Access
Atypical presentations of eosinophilic fasciitis
(MEDKNOW PUBLICATIONS & MEDIA PVT LTD, 2016) SALMAN, ANDAÇ; Ergun, Tulin; Seckin, Dilek; Salman, Andac; Ocak, Esra Sarac; Yucelten, Ayse Deniz; Direskeneli, Haner; Demirkesen, Cuyan; Ekinci, Gazanfer; Bayik, Mahmut
Eosinophilic fasciitis is an uncommon connective tissue disease that may mimic and overlap with other sclerosing disorders such as morphea and lichen sclerosus. Herein, we report four patients (two men and two women, aged 16-64 yeas) with eosinophilic fasciitis. There was overlap with both morphea and lichen sclerosus in 2 patients and with morphoea alone in 1 patient. Magnetic resonance imaging (MRI) was used for diagnosis in three patients and for assessing treatment response in one patient. Eosinophilic fasciitis may co-exist with morhoea and lichen sclerosus. In view of the overlapping clinical and histopathological features of these disorders, MRI may be helful in delineating the conditions by detecting involvement of fascia.
Open Access
Cutaneous leishmaniasis mimicking verrucous carcinoma: A case with an unusual clinical course
(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2015) SALMAN, ANDAÇ; Salman, Andac; Yucelten, Ayse Deniz; Seckin, Dilek; Ergun, Tulin; Demircay, Zeynep
Open Access
Tumor necrosis factor-alpha inhibitors for the treatment of psoriasis patients with liver cirrhosis: A report of four cases with a literature review
(MEDKNOW PUBLICATIONS & MEDIA PVT LTD, 2017) SALMAN, ANDAÇ; Ergun, Tulin; Seckin-Gencosmanoglu, Dilek; Salman, Andac; Qzgen, Zuleyha; Ocak, Esra Sarac; Avsar, Erol; Imeryuz, Nese
Patients with psoriasis are at an increased risk of developing liver disease due to various factors. The existing data regarding the treatment of psoriasis patients with associated liver cirrhosis is limited. We report four patients of psoriasis with liver cirrhosis who were treated with TNF-alpha inhibitors for a mean duration of 35.4 months. Two patients were treated with etanercept, one with adalimumab and one was treated with both infliximab and etanercept. Three patients tolerated the treatment well without any deterioration of liver disease whereas one died of progressive liver disease. Although large-scale, controlled studies are needed, this case series provides insights regarding the long-term safety of TNF-alpha inhibitors in patients with psoriasis and liver cirrhosis.
Open Access
Current Approach to Phototherapy Applications in Dermatology Practice: Part 2. Phototherapy in Vitiligo, Mycosis Fungoides, Atopic Dermatitis, Sclerosing Diseases and Psoriasis
(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2017-06-15) SEÇKİN GENÇOSMANOĞLU, DİLEK; Gencosmanoglu, Dilek Seckin
Many skin diseases can be treated with phototherapy, however, the method choice depends on the disease's characteristics. First-line phototherapy for generalized plaque psoriasis is narrowband ultraviolet B whereas it is psoralen and ultraviolet A for plaque stage mycosis fungoides and ultraviolet A1 for severe localized scleroderma. In this review, efficacy of different phototherapy methods in the most common diseases treated with phototherapy such as vitiligo, mycosis fungoides, atopic dermatitis, sclerosing diseases and psoriasis will be discussed in light of current guidelines.
Open Access
Immunmodulation in the treatment of dermatological diseases
(TURKISH SOC DERMATOLOGY VENEROLOGY, 2013-09-05) SEÇKİN GENÇOSMANOĞLU, DİLEK; Ozgen, Zuleyha; Seckin, Dilek
Immunological effects have an important role in the action mechanisms of the majority of topical and systemic agents, and even some physical treatment modalities in dermatology. Depending on the disease being treated, these effects may be suppression or stimulation of the immune system as well as modulation of the existing functions. Agents that show their effects mainly by immunmodulation in the treatment of dermatological diseases are discussed in the present article. Treatment alternatives included in the article, azathioprine, mycophenolate mofetil, cyclosporine, glucocorticosteroids, topical calcineurin inhibitors, photo(chemo)therapy, intravenous immunoglobuline, interferon, rituximab, omalizumab, imiquimod and extracorporeal photopheresis are discussed focusing especially on their immunomodulatory effects without any mention on their prescribing details, treatment protocols and monitorization aspects.
Open Access
Psychiatric Disorders, Family Functions, and Parent Psychiatric Symptoms in Children and Adolescents with Chronic Dermatological Diseases Treated with Phototherapy
(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2021) SEÇKİN GENÇOSMANOĞLU, DİLEK; Ayyildiz, Didem; Fis, Nese Perdahli; Gumustas, Funda; Seckin, Dilek
Objective: The aim of this study was to examine comorbid psychiatric disorders, family functioning, and parental psychiatric symptoms in children and adolescents with chronic dermatological diseases and compare them with those of healthy controls. Materials and Methods: The research sample consisted of patients between the age of 9 and 18 years (n = 45) with alopecia areata, vitiligo, or psoriasis and a control group (CG) of healthy children and adolescents of the same age (n = 42). The psychiatric diagnoses of cases were established using Schedule for Affective Disorders and Schizophrenia for School Aged Children Present-Lifetime Version. Family assessment device (FAD) was used to evaluate family functioning levels. Parental psychiatric symptom levels were obtained by the Symptom Checklist-90-R. Results: Children and adolescents with chronic dermatological diseases had significantly higher rates of any anxiety disorders and any axis I comorbid psychiatric disorders than healthy controls after adjusting for socioeconomic status (P < 0.05). There were no significant differences in parental psychiatric symptom levels and family functioning levels between two groups; however, families of patients with comorbid psychiatric disorders had significantly higher scores in problem-solving and communication subscales of the FAD when compared to those of patients without psychiatric disorders and CG. Conclusions: Our findings suggest that children and adolescents with chronic dermatological diseases have higher risk for anxiety disorders. When psychiatric disorders co-occur with the dermatological disease in children and adolescents, they may adversely affect the family functioning, in the domains of problem-solving and communication skills.